ProMIS Neurosciences IPO-Jahr
Was ist das IPO-Jahr von ProMIS Neurosciences?
IPO-Jahr von ProMIS Neurosciences, Inc. ist 2007
Was ist die Definition von IPO-Jahr?
Börsengang ist ein öffentliches Angebot, bei dem Aktien eines Unternehmens normalerweise an institutionelle Anleger verkauft werden, die ihrerseits erstmals an einer Wertpapierbörse an die breite Öffentlichkeit verkauft werden.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
IPO-Jahr von Unternehmen in Health Care Sektor auf OTC im Vergleich zu ProMIS Neurosciences
Was macht ProMIS Neurosciences?
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Unternehmen mit ipo-jahr ähnlich ProMIS Neurosciences
- G3 Exploration hat IPO-Jahr von 2006
- Evolis SA hat IPO-Jahr von 2006
- Unity Infraprojects hat IPO-Jahr von 2006
- News Invest hat IPO-Jahr von 2006
- AuStar Gold hat IPO-Jahr von 2006
- Sky and Space Global hat IPO-Jahr von 2006
- ProMIS Neurosciences hat IPO-Jahr von 2007
- Manas Resources hat IPO-Jahr von 2008
- Mastech Digital Inc hat IPO-Jahr von 2008
- MYR Inc hat IPO-Jahr von 2008
- Dana Inc hat IPO-Jahr von 2008
- American Water Works Co hat IPO-Jahr von 2008
- Chromadex Corp hat IPO-Jahr von 2008